Sanofi SNY announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. Following the nod, Wayrilz became the first BTK inhibitor to be approved for treating ITP in the United States. The latest FDA approval was based on data from the phase III LUNA 3 study, which showed…